Jan 30, 2025, 06:15
NSCLC treated with EGFR inhibitors – EGFR Resisters
EGFR Resisters shared a post on X about a recent paper by Otto Manninen et al. published in Oncology:
“NSCLC treated with EGFR inhibitors: the effect of concurrent medications on patient outcomes
‘Conclusions: Among EGFR-TKI-treated NSCLC, the use of TCN, TCS, and DARD can affect treatment outcomes that should be considered in optimal patient care.’ ”
Authors: Otto Manninen, Sanna Iivanainen, Martti Arffman, Jussi Pekka Koivunen.
More posts featuring EGFR Resisters.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 30, 2025, 06:15
Jan 30, 2025, 05:52
Jan 30, 2025, 05:49